Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2012

Open Access 01-12-2012 | Original research

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method

Authors: Rafke Schoffelen, Winette TA van der Graaf, Robert M Sharkey, Gerben M Franssen, William J McBride, Chien-Hsing Chang, Peter Laverman, David M Goldenberg, Wim JG Oyen, Otto C Boerman

Published in: EJNMMI Research | Issue 1/2012

Login to get access

Abstract

Background

In this study, pretargeted immuno-positron-emission tomography [PET] with a bispecific monoclonal anti-carcinoembryonic antigen [CEA] (CEACAM5) × anti-hapten antibody (bispecific monoclonal antibody [bsmAb]) and a small (1.5 kD) peptide labeled with 68Ga was compared to fludeoxyglucose [18F-FDG]-PET for detecting intraperitoneal [i.p.] CEA-expressing human colonic tumor xenografts in nude mice.

Methods

Two groups of female BALB/c nude mice were inoculated with LS174T human colonic tumor cells i.p. One group received 5 MBq 18F-FDG, and the other received intravenous injections of the bsmAb, followed 16 h later with 5 MBq of 68Ga-labeled peptide. One hour after the radiolabeled peptide or FDG was given, micro-PET/computed tomography images were acquired. Thereafter, the uptake of the 68Ga or 18F in dissected tissue was determined.

Results

Within 1 h, high uptake of the 68Ga-labeled peptide in the tumor lesions (23.4 ± 7.2% ID/g) and low background activity levels were observed (e.g., tumor-to-intestine ratio, 58 ± 22). This resulted in a clear visualization of all intra-abdominal tumor lesions ≥ 10 μL and even some tumors as small as 5 μL (2 mm diameter). 18F-FDG efficiently localized in the tumors (8.7 ± 3.1% ID/g) but also showed physiological uptake in various normal tissues (e.g., tumor-to-intestine ratio, 3.9 ± 1.1).

Conclusions

Pretargeted immuno-PET with bsmAb and a 68Ga-labeled peptide could be a very sensitive imaging method for imaging colonic cancer, disclosing occult lesions.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57: 43–66. 10.3322/canjclin.57.1.43PubMedCrossRef
2.
3.
Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001, 2: 533–543. 10.1016/S1470-2045(01)00486-7PubMedCrossRef
4.
5.
Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986, 100: 278–284.PubMed
6.
Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF, Oyen WJ: Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009, 50: 1036–1041. 10.2967/jnumed.109.063040PubMedCrossRef
7.
Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50: 814s-819s.PubMed
8.
Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM: Antibodies against metal chelates. Nature 1985, 316: 265–268. 10.1038/316265a0PubMedCrossRef
9.
Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH: Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003, 44: 400–411.PubMed
10.
Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM: Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002, 1: 553–563.PubMed
11.
Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005, 11: 1250–1255. 10.1038/nm1322PubMedCrossRef
12.
Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989, 30: 1358–1366.PubMed
13.
Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM: Experimental pretargeting studies of cancer with a humanized anti-CEA × murine anti-[In-DTPA] bispecific antibody construct and a (99 m)Tc-/(188)Re-labeled peptide. Bioconjug Chem 2000, 11: 842–854. 10.1021/bc0000379PubMedCrossRef
14.
Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ: The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005, 104: 2658–2670. 10.1002/cncr.21569PubMedCrossRef
15.
Park IJ, Kim HC, Yu CS, Ryu MH, Chang HM, Kim JH, Ryu JS, Yeo JS, Kim JC: Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006, 32: 941–947. 10.1016/j.ejso.2006.05.019PubMedCrossRef
16.
Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, Gomez-Rio M, Bellon-Guardia M, Ramos-Font C, Rebollo-Aguirre AC, Cabello-Garcia D, Ferron-Orihuela A: Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007, 34: 859–867. 10.1007/s00259-006-0274-4PubMedCrossRef
17.
Tzimas GN, Koumanis DJ, Meterissian S: Positron emission tomography and colorectal carcinoma: an update. J Am Coll Surg 2004, 198: 645–652. 10.1016/j.jamcollsurg.2003.11.015PubMedCrossRef
18.
Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, Mortelmans L, Penninckx F: Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001, 27: 175–179. 10.1053/ejso.2000.1075PubMedCrossRef
19.
Pelosi E, Deandreis D: The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007, 33: 1–6. 10.1016/j.ejso.2006.10.020PubMedCrossRef
20.
Herbertson RA, Scarsbrook AF, Lee ST, Tebbutt N, Scott AM: Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol 2009, 64: 225–237. 10.1016/j.crad.2008.08.008PubMedCrossRef
21.
Rosenbaum SJ, Lind T, Antoch G, Bockisch A: False-positive FDG PET uptake--the role of PET/CT. Eur Radiol 2006, 16: 1054–1065. 10.1007/s00330-005-0088-yPubMedCrossRef
22.
Metser U, Miller E, Lerman H, Even-Sapir E: Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am J Roentgenol 2007, 189: 1203–1210. 10.2214/AJR.07.2083PubMedCrossRef
23.
Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, Figer A, Metser U: Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004, 232: 815–822. 10.1148/radiol.2323031065PubMedCrossRef
24.
Dirisamer A, Schima W, Heinisch M, Weber M, Lehner HP, Haller J, Langsteger W: Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 2009, 69: 536–541. 10.1016/j.ejrad.2007.11.032PubMedCrossRef
25.
Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH: Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008, 49: 158–163.PubMedCrossRef
26.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72: 77–89. 10.1016/0022-1759(84)90435-6PubMedCrossRef
27.
Morel A, Darmon M, Delaage M: Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol 1990, 27: 995–1000. 10.1016/0161-5890(90)90122-GPubMedCrossRef
28.
Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH: Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006, 103: 6841–6846. 10.1073/pnas.0600982103PubMedCentralPubMedCrossRef
29.
Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Ballance C, Pawlyk D, Varga D, Hansen HJ: Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res 1990, 50: 2823–2831.PubMed
30.
McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM: Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006, 47: 1678–1688.PubMed
31.
Fraker PJ, Speck JC Jr: Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978, 80: 849–857. 10.1016/0006-291X(78)91322-0PubMedCrossRef
32.
Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, van der Graaf WT, Oyen WJ, Boerman OC: Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 2010, 9: 1019–1027. 10.1158/1535-7163.MCT-09-0862PubMedCentralPubMedCrossRef
33.
Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC: Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med 2009, 50: 139–147.PubMedCrossRef
34.
Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP: Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med 2006, 47: 1867–1874.PubMed
35.
Meyers MA: Dynamic radiology of the abdomen: normal and pathologic anatomy. 5th edition. New York: Springer-Verlag; 2000.
36.
De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L: Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging 2009, 34: 391–402. 10.1007/s00261-008-9405-7PubMedCrossRef
37.
Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, Rossi EA, Eek A, Oyen WJ, Boerman OC: Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 2010, 51: 1780–1787. 10.2967/jnumed.110.079376PubMedCrossRef
38.
Sharkey RM, Primus FJ, Goldenberg DM: Antibody protein dose and radioimmunodetection of GW-39 human colon tumor xenografts. Int J Cancer 1987, 39: 611–617. 10.1002/ijc.2910390512PubMedCrossRef
39.
Moshakis V, McIlhinney RA, Raghavan D, Neville AM: Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies. Br J Cancer 1981, 44: 91–99. 10.1038/bjc.1981.153PubMedCentralPubMedCrossRef
40.
Hagan PL, Halpern SE, Dillman RO, Shawler DL, Johnson DE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS, Carlo D: Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986, 27: 422–427.PubMed
41.
Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM: Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft. Int J Cancer 1989, 44: 1041–1047. 10.1002/ijc.2910440617PubMedCrossRef
42.
Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM: Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008, 246: 497–507. 10.1148/radiol.2462070229PubMedCrossRef
43.
Chowdhury FU, Shah N, Scarsbrook AF, Bradley KM: [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J 2010, 86: 174–182. 10.1136/pgmj.2009.079087PubMedCrossRef
44.
Esteves FP, Schuster DM, Halkar RK: Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 2006, 36: 169–181. 10.1053/j.semnuclmed.2005.12.002PubMedCrossRef
45.
Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA: Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 2006, 47: 999–1006.PubMed
46.
McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM: A novel method of 18F radiolabeling for PET. J Nucl Med 2009, 50: 991–998. 10.2967/jnumed.108.060418PubMedCrossRef
47.
Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC: A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med 2010, 51: 454–461. 10.2967/jnumed.109.066902PubMedCentralPubMedCrossRef
Metadata
Title
Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method
Authors
Rafke Schoffelen
Winette TA van der Graaf
Robert M Sharkey
Gerben M Franssen
William J McBride
Chien-Hsing Chang
Peter Laverman
David M Goldenberg
Wim JG Oyen
Otto C Boerman
Publication date
01-12-2012
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2012
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/2191-219X-2-5

Other articles of this Issue 1/2012

EJNMMI Research 1/2012 Go to the issue

Original research

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Preliminary research

Assessment of bone graft incorporation by 18 F-fluoride positron-emission tomography/computed tomography in patients with persisting symptoms after posterior lumbar interbody fusion

Original research

Breath-hold CT attenuation correction for quantitative cardiac SPECT

Short communication

Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates

Original research

The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant

Original research

Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy